| |  Online-Ressource |
|---|
| Verfasst von: | Mirna, Moritz [VerfasserIn]  |
|---|
| | Topf, Albert [VerfasserIn] |
|---|
| | Wernly, Bernhard [VerfasserIn] |
|---|
| | Rezar, Richard [VerfasserIn] |
|---|
| | Paar, Vera [VerfasserIn] |
|---|
| | Jung, Christian [VerfasserIn] |
|---|
| | Salmhofer, Hermann [VerfasserIn] |
|---|
| | Kopp, Kristen [VerfasserIn] |
|---|
| | Hoppe, Uta C. [VerfasserIn] |
|---|
| | Schulze, Paul Christian [VerfasserIn] |
|---|
| | Kretzschmar, Daniel [VerfasserIn] |
|---|
| | Schneider, Markus P. [VerfasserIn] |
|---|
| | Schultheiß, Ulla Teresa [VerfasserIn] |
|---|
| | Sommerer, Claudia [VerfasserIn] |
|---|
| | Paul, Katharina [VerfasserIn] |
|---|
| | Wolf, Gunter [VerfasserIn] |
|---|
| | Lichtenauer, Michael [VerfasserIn] |
|---|
| | Busch, Martin [VerfasserIn] |
|---|
| Titel: | Novel biomarkers in patients with chronic kidney disease |
|---|
| Titelzusatz: | an analysis of patients enrolled in the GCKD-study |
|---|
| Verf.angabe: | Moritz Mirna, Albert Topf, Bernhard Wernly, Richard Rezar, Vera Paar, Christian Jung, Hermann Salmhofer, Kristen Kopp, Uta C. Hoppe, P. Christian Schulze, Daniel Kretzschmar, Markus P. Schneider, Ulla T. Schultheiss, Claudia Sommerer, Katharina Paul, Gunter Wolf, Michael Lichtenauer and Martin Busch |
|---|
| E-Jahr: | 2020 |
|---|
| Jahr: | 24 March 2020 |
|---|
| Fussnoten: | Gesehen am 15.05.2020 |
|---|
| Titel Quelle: | Enthalten in: Journal of Clinical Medicine |
|---|
| Ort Quelle: | Basel : MDPI, 2012 |
|---|
| Jahr Quelle: | 2020 |
|---|
| Band/Heft Quelle: | 9(2020,3) Artikel-Nummer 886, 17 Seiten |
|---|
| ISSN Quelle: | 2077-0383 |
|---|
| Abstract: | Background: Chronic kidney disease (CKD) and cardiovascular diseases (CVD) often occur concomitantly, and CKD is a major risk factor for cardiovascular mortality. Since some of the most commonly used biomarkers in CVD are permanently elevated in patients with CKD, novel biomarkers are warranted for clinical practice. Methods: Plasma concentrations of five cardiovascular biomarkers (soluble suppression of tumorigenicity (sST2), growth differentiation factor 15 (GDF-15), heart-type fatty acid-binding protein (H-FABP), insulin-like growth factor-binding protein 2 (IGF-BP2), and soluble urokinase plasminogen activator receptor) were analyzed by means of enzyme-linked immunosorbent assay (ELISA) in 219 patients with CKD enrolled in the German Chronic Kidney Disease (GCKD) study. Results: Except for sST2, all of the investigated biomarkers were significantly elevated in patients with CKD (2.0- to 4.4-fold increase in advanced CKD (estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² body surface area (BSA)) and showed a significant inverse correlation with eGFR. Moreover, all but H-FABP and sST2 were additionally elevated in patients with micro- and macro-albuminuria. Conclusions: Based on our findings, sST2 appears to be the biomarker whose diagnostic performance is least affected by decreased renal function, thus suggesting potential viability in the management of patients with CVD and concomitant CKD. The predictive potential of sST2 remains to be proven in endpoint studies. |
|---|
| DOI: | doi:10.3390/jcm9030886 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.3390/jcm9030886 |
|---|
| | Volltext: https://www.mdpi.com/2077-0383/9/3/886 |
|---|
| | DOI: https://doi.org/10.3390/jcm9030886 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | biomarkers |
|---|
| | CKD |
|---|
| | CVD |
|---|
| | sST2 |
|---|
| K10plus-PPN: | 1698315643 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Novel biomarkers in patients with chronic kidney disease / Mirna, Moritz [VerfasserIn]; 24 March 2020 (Online-Ressource)
